Attorney Docket No: ADAM-046XX
Inventor(s): Michael Valentine Agrez et al.
Application No. 10/019,816
TC Art Unit: 1643/Examiner: Karen A. Canella
OA Date: 08/09/07/Resp. Date: 1/09/07

AMENDMENT TO THE CLAIMS

1. - 216. (Cancelled)

217. (Currently Amended) A method for inhibiting growth of a cancer cell, the method comprising:

providing a

~~treating the cancer cell with an effective amount of a polypeptide, (a) the~~ polypeptide comprising a cytoplasmic fragment of a β integrin subunit selected from the group consisting of β3, β5 and β6, ~~whereby~~ wherein the polypeptide provides a binding domain of the β integrin subunit for ~~a~~ ERK2 MAP kinase and wherein said binding domain incorporates an amino acid linker sequence that links opposite end regions of the binding domain together, the linker sequence being non-essential for binding of the MAP kinase to said binding domain or

~~(b) the~~ providing a polypeptide having a modified amino acid sequence compared to ~~said~~ binding domain, wherein said modified amino acid sequence has greater than 60% amino acid sequence homology with said binding domain, binds to the MAP kinase and is other than a fragment of said β integrin subunit; and

~~wherein (a) said binding domain incorporates an amino acid linker sequence that links opposite end regions of the binding domain together, the linker sequence being non-essential for binding of the MAP kinase to said binding domain; and (b) said modified amino acid sequence has greater than 60% amino acid sequence homology with said binding domain and binds to the MAP kinase and is other than a fragment of said β integrin subunit or other β integrin subunit; and wherein the MAP kinase is ERK2~~

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290

treating a cancer cell with an effective amount of said polypeptide.

218. (Currently Amended) A method according to claim 217, wherein the polypeptide comprises ~~the~~said binding domain for ~~the~~a MAP kinase.

219. (Currently Amended) A method according to claim 217, wherein the polypeptide comprises ~~the~~said modified amino acid sequence.

220. (Cancelled)

221. (Previously Presented) A method according to claim 217, wherein the polypeptide is coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.

222-224. (Cancelled)

225. (Previously Presented) A method according to claim 217 wherein the cancer cell is a colon cancer cell.

226-237. (Cancelled)

238. (Previously Presented) A method according to claim 217, wherein the cancer cell is a cancer cell of a cancer selected from the group consisting of cancer of the lip, tongue, salivary glands, gums, floor and other areas of the mouth, oropharynx, nasopharynx, hypopharynx and other oral cavities, oesophagus,

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290

stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

239-243. (Cancelled)

244. (Previously Presented) A method according to claim 217 wherein the polypeptide comprises an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22), RSRARYEMASNPLYR (SEQ ID No. 23), and RSKAKNPLYR (SEQ ID No. 3).

245-265. (Cancelled)

266-269. (Cancelled)

270-271. (Cancelled)

272. (Currently Amended) A method according to claim 217~~ or 266~~ wherein the β integrin subunit is β6.

273-274. (Cancelled)

275. (Previously Presented) A method according to claim 219 wherein all of the amino acids in the amino acid linker sequence of said binding domain are deleted in the modified amino acid sequence.

276. (Cancelled)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290

277. (Currently Amended) A method according to claim 217~~ or 220~~, wherein the polypeptide is ~~greater than~~between about 5 amino acids and ~~up to 20~~about 25 amino acids in length.

278. (Cancelled)

279-282. (Cancelled)